AnaptysBio announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and investments greater than $575M as of December 31, 2022, notwithstanding the potential full execution of the Stock Repurchase Plan, the company reiterates its previous guidance that it anticipates having approximately 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANAB:
- AnaptysBio Announces Stock Repurchase Plan
- AnaptysBio downgraded to Market Perform from Outperform at Raymond James
- AnaptysBio announces portfolio update, discloses $575M in cash to end 2022
- AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
- AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
